Skip to main content
SpringerLink
Log in

Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290

    Article  CAS  Google Scholar 

  2. Pilepich MV et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 15: 1013–1021

    Article  CAS  Google Scholar 

  3. Lawton CA et al. (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937–946

    Article  CAS  Google Scholar 

  4. Hanks GE et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21: 3972–3978

    Article  CAS  Google Scholar 

  5. Pilepich MV et al. (2001) Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243–1252

    Article  CAS  Google Scholar 

  6. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Michelmore, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Radiation Oncology and Head of the Federation of Oncology at the Centre Hospitalier Universitaire de Grenoble, Grenoble, France

    Michel Bolla

Authors
  1. Michel Bolla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Bolla.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolla, M. Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?. Nat Rev Urol 2, 536–537 (2005). https://doi.org/10.1038/ncpuro0331

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0331

  • Springer Nature Limited

Search

Navigation